The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers ...

The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved ...

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Moderna and Merck's personalised mRNA vaccine shows promising Phase 3 results in melanoma treatment, potentially ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

Shares of Moderna Inc MRNA had their best day in history as a public company this week, with the stock soaring on positive ...

Even with a modest 25% success rate for the company's current phase 2 programs, Moderna should be able to launch enough new ...